Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Hiba M. Shendi"'
Autor:
Amna Ali Al Kuwaiti, Ahmed Darwaish Al Dhaheri, Moza Al Hassani, Zbigniew Ruszczak, Ahmad Alrustamani, Walid Abuhammour, Gehad El Ghazali, Suleiman Al-Hammadi, Hiba M. Shendi
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundChronic granulomatous disease (CGD) is a genetic disorder caused by defective oxidative burst within phagocytes, manifesting as recurrent, severe infections as well as hyperinflammation.ObjectiveThis is the first report from the United Arab
Externí odkaz:
https://doaj.org/article/8328e698aa92446a9c28df5d7da0718d
Autor:
Suleiman Al-Hammadi, Najla S. Alkuwaiti, Ghassan A. Ghatasheh, Huda Al Dhanhani, Hiba M. Shendi, Abdulghani S. Elomami, Farida Almarzooqi, Abdul-Kader Souid
Publikováno v:
Case Reports in Immunology, Vol 2020 (2020)
Background. The Bacillus Calmette–Guérin (BCG) and rotavirus vaccines are live-attenuated preparations. In the United Arab Emirates, these products are universally administered to the young infants. This unguided practice does not account for the
Externí odkaz:
https://doaj.org/article/21a8ca0ede9542f7adf719a4fba2aa03
Publikováno v:
Journal of clinical rheumatology : practical reports on rheumaticmusculoskeletal diseases. 20(2)
Hyperimmunoglobulin D and periodic fever syndrome (HIDS) is a rare, autoinflammatory condition caused by mutations in the mevalonate kinase gene. There is no standard treatment for HIDS, and randomized controlled trials are lacking. Corticosteroids,
Publikováno v:
Rheumatology international. 32(1)
Hyperimmunoglobulin D and periodic fever syndrome (HIDS) is a rare, hereditary autoinflammatory condition, characterized by recurrent inflammatory episodes. There is no proven treatment for HIDS, but various drugs including, non-steroidal anti-inflam
Autor:
Alison Donnelly, John Thompson, Cathal Laurence Steele, J. David M. Edgar, Lisa Devlin, Hiba M. Shendi, Niall Conlon, Matthew Doré
Publikováno v:
Clinical and Translational Allergy
Results MA testing has increased annually since its introduction in 2010. Spending on MA diagnostics exceeded £20,000 in 2013. Increases in test numbers were observed across a range of allergen groups during the time period and suggests routine orde